Top in hem/onc: Bone health after cancer treatment, FDA approval of Opdualag

Certain cancer treatments and prolonged cancer survival can increase the risk of bone loss.

Women with breast cancer and men with prostate cancer are at highest risk for bone loss because of reducing or blocking hormones that occur during treatment. It was the top story in hematology/oncology last week.

The second top story covered the FDA’s approval of relatimab plus nivolumab for patients with unresectable or metastatic melanoma.

Read these and more top stories in hematology/oncology below:

Physicians must ‘take responsibility’ for bone health of cancer survivors

Bone loss is a natural part of aging — especially due to menopause for women — but certain cancer treatments and prolonged cancer survival can increase the risk for bone loss and the related outcome of fractures. Read more.

FDA approves Opdualag for unresectable or metastatic melanoma

The FDA approved relatlimab plus nivolumab for treatment of patients aged 12 years or older with unresectable or metastatic melanoma. Read more.

FDA approves Keytruda for advanced endometrial carcinoma subset

The FDA approved pembrolizumab for certain women with microsatellite instability-high or mismatch repair-deficient advanced endometrial cancer. Read more.

Trastuzumab deruxtecan shows ‘terrific activity’ in second line for breast cancer subset

Trastuzumab deruxtecan reduced risk for disease progression or death compared with trastuzumab emtansine among patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane. Read more.

FDA approves Pluvicto for certain men with advanced prostate cancer

The FDA approved lutetium Lu 177 vipivotide tetraxetan for treatment of certain men with advanced prostate cancer. Read more.